Deconvoluting drug interactions using <i>M. tuberculosis</i> physiologic processes: transcriptional disaggregation of the BPaL regimen <i>in vivo</i>
A key challenge in preclinical tuberculosis drug development is identifying optimal antibiotic combinations. Drug interactions are complex because one drug may affect <i>Mycobacterium tuberculosis</i> (<i>Mtb</i>) physiology in a way that alters the activity of another drug. Conventional pharmacodynamic evaluation based on colony-forming units (CFU) does not provide information about this physiologic interaction because CFU enumerates bacteria but does not give information about the drug's effect on bacterial cellular processes. SEARCH-TB is a novel pharmacodynamic (PD) approach that uses targeted <i>in vivo</i> transcriptional profiling to evaluate drug effects on <i>Mtb</i> physiology. To evaluate SEARCH-TB's capacity to elucidate drug interactions, we deconstructed the BPaL (bedaquiline, pretomanid, and linezolid) regimen in the BALB/c high-dose aerosol mouse infection model, measuring the effect of 2-, 7-, and 14-day treatment with drugs in monotherapy, pairwise combinations, and as a three-drug combination. Monotherapy induced drug-specific <i>Mtb</i> transcriptional responses by day 2 with continued evolution over 14 days. Bedaquiline dominated pairwise combinations with pretomanid and linezolid, whereas the pretomanid-linezolid combination induced a transcriptional profile intermediate between either drug. In the three-drug BPaL regimen, adding both pretomanid and linezolid to bedaquiline yielded a greater transcriptional response than expected, based on pairwise results. This work demonstrates that physiologic perturbations induced by a single drug may be modified in complex ways when drugs are combined. This establishes proof of concept that SEARCH-TB provides a highly granular readout of drug interactions <i>in vivo,</i> providing information distinct from CFU burden and suggesting a future where regimen selection is informed by <i>in vivo</i> molecular measures of <i>Mtb</i> physiology.
Authors
- Gregory T. Robertson (ORCID: https://orcid.org/0000-0001-7157-4034)
- Nicholas D. Walter (ORCID: https://orcid.org/0000-0003-0126-1993)
- Elizabeth A. Wynn (ORCID: https://orcid.org/0000-0002-5857-4483)
- Christian Dide-Agossou (ORCID: https://orcid.org/0000-0001-9854-1785)
- Michael A. Lyons (ORCID: https://orcid.org/0000-0003-0143-6626)
- Andrés Obregón‐Henao (ORCID: https://orcid.org/0000-0002-6496-6790)
- Camille M. Moore (ORCID: https://orcid.org/0000-0002-7363-8684)
- Karen Rossmassler (ORCID: https://orcid.org/0000-0003-4069-744X)
- Reem Al Mubarak (ORCID: https://orcid.org/0000-0002-2303-7004)
- Martin I. Voskuil (ORCID: https://orcid.org/0000-0002-9565-7923)
- Jo Hendrix
Institutions
- National Jewish Health (US)
- University of Colorado Anschutz Medical Campus (US)
- University of Colorado Denver (US)
- Colorado State University (US)
Publication Details
- Journal
- Antimicrobial Agents and Chemotherapy
- Published
- 2025-09-18
- DOI
- https://doi.org/10.1128/aac.00492-25
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00